PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21424914-11 2011 In the rosiglitazone group, FPG, PPG, HbA1c, insulin, HOMA-IR, IL-6, and TNF-alpha levels decreased significantly after 12 weeks compared with the basal levels. Rosiglitazone 7-20 interleukin 6 Homo sapiens 54-67 19673614-10 2009 Also, the patients who received rosiglitazone had reduced inflammatory responses to infection, compared with the patients who received a placebo (ie, interleukin-6 levels at 24 h [p < .005] and at 48 h [p = .013] and monocyte chemoattractant protein-1 level at 48 h [p = .05]). Rosiglitazone 32-45 interleukin 6 Homo sapiens 150-163 21031343-0 2011 Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes. Rosiglitazone 11-24 interleukin 6 Homo sapiens 125-129 21031343-7 2011 There was a considerable amelioration of hsCRP, WBC, adiponectin, IL-6, systolic and diastolic BP with rosiglitazone/metformin combined treatment as compared to baseline (p < 0.05) and MET group (p < 0.05). Rosiglitazone 103-116 interleukin 6 Homo sapiens 66-70 21031343-12 2011 CONCLUSIONS: Both rosiglitazone/metformin combination therapy and metformin monotherapy decreased serum vaspin levels through glucose and insulin sensitivity regulation, while they exerted differential effects on adiponectin, IL-6 and other cardiovascular risk factors in drug-naive patients with T2DM. Rosiglitazone 18-31 interleukin 6 Homo sapiens 226-230 20921996-0 2010 Rosiglitazone regulates IL-6-stimulated lipolysis in porcine adipocytes. Rosiglitazone 0-13 interleukin 6 Homo sapiens 24-28 20921996-2 2010 However, the effects of the anti-diabetic drug rosiglitazone on IL-6-stimulated lipolysis and the underlying molecular mechanism are largely unknown. Rosiglitazone 47-60 interleukin 6 Homo sapiens 64-68 20921996-3 2010 In this study, we demonstrated that rosiglitazone suppressed IL-6-stimulated lipolysis in differentiated porcine adipocytes by inactivation of extracellular signal-related kinase (ERK). Rosiglitazone 36-49 interleukin 6 Homo sapiens 61-65 20921996-5 2010 In addition, rosiglitazone significantly reversed IL-6-induced down-regulation of several genes such as perilipin A, peroxisome proliferators activated receptor gamma (PPAR&gamma;), and fatty acid synthetase, as well as the up-regulation of IL-6 mRNA. Rosiglitazone 13-26 interleukin 6 Homo sapiens 50-54 20921996-5 2010 In addition, rosiglitazone significantly reversed IL-6-induced down-regulation of several genes such as perilipin A, peroxisome proliferators activated receptor gamma (PPAR&gamma;), and fatty acid synthetase, as well as the up-regulation of IL-6 mRNA. Rosiglitazone 13-26 interleukin 6 Homo sapiens 245-249 20921996-6 2010 However, mRNA expression of PPAR&gamma; coactivator-1 alpha (PCG-1&alpha;) was enhanced by rosiglitazone in IL-6-stimulated adipocytes. Rosiglitazone 99-112 interleukin 6 Homo sapiens 116-120 20921996-7 2010 These results indicate that rosiglitazone suppresses IL-6-stimulated lipolysis in porcine adipocytes through multiple molecular mechanisms. Rosiglitazone 28-41 interleukin 6 Homo sapiens 53-57 20003221-14 2009 The concentration of IL-6 following rosiglitazone exposure did not significantly decrease comparing to control. Rosiglitazone 36-49 interleukin 6 Homo sapiens 21-25 19782427-6 2009 The importance of ERK activation in mediating the synergism of the two cytokines is further confirmed by the inhibitory effect of the anti-diabetic drug rosiglitazone and ERK blockers on IP-10, MIG and IL-6 secretion. Rosiglitazone 153-166 interleukin 6 Homo sapiens 202-206 19923143-9 2010 The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, rosiglitazone, attenuated HG-induced PKC but not HG- or BK- induced MAPK p42/44 activation and reduced HG-stimulated VEGF, along with IL-6, CCL-2 and TGF-beta secretion. Rosiglitazone 75-88 interleukin 6 Homo sapiens 209-213 19443277-5 2009 Dual treatment of rosiglitazone and losartan provided synergistic effect in reducing ICAM-1, IL-6 and ATR1 expression and NF-kappaB and ERK1/2 activation induced by the conditioned media when compared with monotherapy. Rosiglitazone 18-31 interleukin 6 Homo sapiens 93-97 18541328-8 2008 Plasma IL-6 (-25%), CRP (-55%) and GGT (-25%) concentrations declined significantly in the rosiglitazone group. Rosiglitazone 91-104 interleukin 6 Homo sapiens 7-11 19155534-9 2009 The PPAR-gamma antagonist, GW9662, significantly attenuated the inhibitory action of rosiglitazone on the increased synthesis of IL-6 and ATR1 protein. Rosiglitazone 85-98 interleukin 6 Homo sapiens 129-133 17141246-3 2007 The objectives of this study were to examine the influence of PPAR gamma and its agonist (rosiglitazone) on the TNFalpha, IL-6, IL-8 and IL-10 gene expression in monocytes of patients with diabetic macroangiopathy and to analyse obtained results in context of selected atherogenic factors ant direct indicators of endothelial lesion. Rosiglitazone 90-103 interleukin 6 Homo sapiens 122-126 18583261-5 2008 RESULTS: In group A, rosiglitazone treatment resulted in significantly reduced serum hs-CRP, IL-1beta, IL-6, TNF-alpha, FPG and insulin resistance index (P<0.01). Rosiglitazone 21-34 interleukin 6 Homo sapiens 103-107 17922475-9 2008 IL-6 production was stimulated by PMA in both C and T2D patients; this effect was prevented by rosiglitazone in a Sr202-inhibitable manner. Rosiglitazone 95-108 interleukin 6 Homo sapiens 0-4 15526907-6 2004 Importantly, PPARgamma agonists troglitazone, rosiglitazone, and 15-deoxy-delta(12, 14)-prosglandin J2 significantly decreased the up expression of TNF-alpha and IL-6 in HMCL supernatants stimulated by IL-1beta. Rosiglitazone 46-59 interleukin 6 Homo sapiens 162-166 17224000-11 2007 Significant decreases in resistin, C-reactive protein, TNF-alpha, IL-6 and IL-18 were seen in the rosiglitazone-treated patients but not in the metformin-treated patients. Rosiglitazone 98-111 interleukin 6 Homo sapiens 66-70 16137694-7 2006 Rosiglitazone reduced the incremental area under the curves (dAUCs) for IL-6 (-63%, p<0.01) and IL-8 (-16%, p<0.05). Rosiglitazone 0-13 interleukin 6 Homo sapiens 72-76 16137694-9 2006 CONCLUSIONS: Rosiglitazone attenuated the postprandial increases of neutrophils, IL-6 and IL-8 in patients with type 2 diabetes. Rosiglitazone 13-26 interleukin 6 Homo sapiens 81-85 16137694-12 2006 Rosiglitazone attenuated the postprandial increases of neutrophils, IL-6 and IL-8 in patients with type 2 diabetes. Rosiglitazone 0-13 interleukin 6 Homo sapiens 68-72 16223437-1 2005 The objective was to investigate the relationship between homocysteine (HCY), peroxisome proliferator-activated receptors (PPAR)-gamma and the expression of interleukin 6 (IL-6) and microsomal prostaglandin E synthase (mPGES) by peripheral blood mononuclear cell (PBMC) culture in vitro, as well as to look at the intervention with HCY and PPAR-gamma activators (troglitazone and rosiglitazone). Rosiglitazone 380-393 interleukin 6 Homo sapiens 157-170 14749206-5 2004 Twenty-four-week treatment with rosiglitazone (8 mg/day) compared with placebo significantly increased the expression of adiponectin, peroxisome proliferator-activated receptor-gamma (PPARgamma), and PPARgamma coactivator 1 and decreased IL-6 expression. Rosiglitazone 32-45 interleukin 6 Homo sapiens 238-242 12163427-4 2002 The purpose of this analysis was to determine whether rosiglitazone alters serum concentrations of CRP, IL-6, MMP-9, and white blood cell count (WBC) and to examine the relationship of these effects with demographic and disease variables. Rosiglitazone 54-67 interleukin 6 Homo sapiens 104-108 12509942-8 2002 PPARgamma agonists troglitazone, rosiglitazone, and 15-deoxy-Delta(12, 14)-prosglandin J(2) significantly decreased the upexpression of TNF-alpha and IL-6 in HMCL supernatants stimulated by IL-1beta. Rosiglitazone 33-46 interleukin 6 Homo sapiens 150-154 12163427-7 2002 The percentage reduction in mean IL-6 was small and similar in the rosiglitazone and placebo groups. Rosiglitazone 67-80 interleukin 6 Homo sapiens 33-37 34170488-4 2022 We aimed to study the effect of RGZ onto inflammation-induced secretion of CXCL10, IFNgamma, TNFalpha, interleukin (IL)-6 and IL-8 by human CD4 + T and DCs, and onto IFNgamma/TNFalpha-dependent signaling in human cardiomyocytes associated with chemokine release. Rosiglitazone 32-35 interleukin 6 Homo sapiens 103-121 34170488-8 2022 In human cardiomyocytes, RGZ impaired IFNgamma/TNFalpha signal transduction, blocking the phosphorylation/nuclear translocation of signal transducer and activator of transcription 1 (Stat1) and nuclear factor-kB (NF-kB), in association with a significant decrease in CXCL10 expression, IL-6 and IL-8 release. Rosiglitazone 25-28 interleukin 6 Homo sapiens 286-290 30488141-4 2019 Treatment with RSG ameliorated axonal injury, cell apoptosis, glia activation, and the release of inflammatory factors such as TNF-alpha, IL-1beta, and IL-6. Rosiglitazone 15-18 interleukin 6 Homo sapiens 152-156